181 237

Cited 0 times in

Tumor Necrosis Factor 길항제 치료 실패 후 Methotrexate로 관해 유도와 유지 치료가 가능했던 크론병 1예

Other Titles
 A Case of Crohn's Disease Showing Favorable Response to Induction and Maintenance Therapy with Methotrexate after Failure of Anti-tumor Necrosis Factor Therapy 
 최정란  ;  윤각원  ;  박유미  ;  김지현  ;  윤영훈  ;  박효진  ;  박재준 
 Korean Journal of Gastroenterology, Vol.66(4) : 231-236, 2015 
Journal Title
 Korean Journal of Gastroenterology 
Issue Date
Methotrexate ; Maintenance ; Crohn disease ; Remission induction
Thanks to the introduction of immumomodulators and biologics, therapeutic approaches in Crohn’s disease have changed significantly during the past decade. Although new biologic therapy has dramatically improved the treatment of Crohn’s disease, a substantial number of patients are refractory to these therapies or lose their initial response. Methotrexate (MTX) is a structural analogue of folic acid that can competitively inhibit the binding of dihydrofolic acid to the enzyme dihydrofolate reductase and has been widely used as immunomodulator in rheumatology area for patients with rheumatoid arthritis and psoriasis. Although MTX has also been shown to be an effective agent for remission induction and maintenance of remission in Crohn’s disease, the use of MTX in Crohn’s disease has not yet been reported in Korea. Herein, we report a case of Crohn’s disease patient who was successfully treated with MTX after treatment failure with thiopurine and anti-tumor necrosis factor.
Files in This Item:
T999901546.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jie-Hyun(김지현) ORCID logo https://orcid.org/0000-0002-9198-3326
Park, Yoo Mi(박유미) ORCID logo https://orcid.org/0000-0002-3642-7300
Park, Jae Jun(박재준)
Park, Hyo Jin(박효진) ORCID logo https://orcid.org/0000-0003-4814-8330
Yun, Gak Won(윤각원)
Youn, Young Hoon(윤영훈) ORCID logo https://orcid.org/0000-0002-0071-229X
Choi, Jung Ran(최정란)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.